FDA approves Amgen heart drug
By Staff Report / Wednesday, April 15th, 2015 / Health Care & Life Science, Latest news, Technology, Top Stories, Tri-County Public Companies / Comments Off on FDA approves Amgen heart drug
The drug is the first chronic heart failure medication approved by the FDA in nearly a decade.
Amgen alum speeds toward OK for chin drug
By Erika Martin / Friday, April 10th, 2015 / East Ventura County, Health Care & Life Science, Latest news, Technology, Top Stories, Tri-County Public Companies / Comments Off on Amgen alum speeds toward OK for chin drug
Known as ATX-101, the facial injection for the treatment of double chins has been recommended for approval by an FDA advisory committee.
Amgen touts positive results with new heart health drug
By Erika Martin / Friday, March 20th, 2015 / East Ventura County, Health Care & Life Science, Latest news, Technology, Top Stories, Tri-County Public Companies / Comments Off on Amgen touts positive results with new heart health drug
If approved, it will be the Thousand Oaks-based biotech giant’s first new drug on the market since the FDA’s landmark approval of the first-ever biosimilar drug on the American market.
Amgen braces for battle over biosimilars
By Erika Martin / Friday, March 13th, 2015 / East Ventura County, Latest news, Technology, Top Stories / Comments Off on Amgen braces for battle over biosimilars
On March 9, a company memo announced its plans to shutter San Francisco facilities once belonging to Onyx Pharmaceuticals and lay off 300 employees there.
Region wins as Amgen shuffles jobs
By Staff Report / Tuesday, March 10th, 2015 / Latest news, Technology, Top Stories / Comments Off on Region wins as Amgen shuffles jobs
In a company memo circulated yesterday, Amgen CEO Robert Bradway said the firm will begin reconsolidating oncology operations into its Thousand Oaks headquarters.
Amgen’s portfolio threatened as FDA paves path for lower-cost drugs
By Staff Report / Friday, March 6th, 2015 / Latest news, Technology, Top Stories, Tri-County Public Companies / Comments Off on Amgen’s portfolio threatened as FDA paves path for lower-cost drugs
Zarxio, the first biopharmaceutical copycat approved in the U.S., will pave the way for lower-cost alternatives to existing treatments.
Tri-county cities return as major features in Amgen Tour of California
By Staff Report / Tuesday, February 24th, 2015 / Features, Latest news, Top Stories, Tourism, Tri-County Economy / Comments Off on Tri-county cities return as major features in Amgen Tour of California
One of the most prestigious races in US cycling will pedal through a handful of tri-county cities this May.
